Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABNCoV2 Vaccine in Healthy Adults (COUGH-1)
NCT04839146Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of abncov2 in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Radboud University Medical Center. Primary endpoints: Number of at Least Possibly Related Grade 3 Adverse Events (AE) and Serious Adverse Events (SAE) at 28 weeks and Concentration of ABNCoV2-specific Antibodies at 14 days. Started Mar 2021; status: completed.
02
Drugs
abncov2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04839146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839146.